DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00044694

CompletedPhase 2

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus

Lead sponsor

AstraZeneca

Asset

Exenatide

GLP-1 agonist

Listed sites

33

Recruiting sites

—

Enrollment

156

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 27-45•HbA1c 7-8%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00044694
Org study ID2993-116

Timeline

Milestones

Study first posted2002-09-05estimated
Last update posted2015-02-20estimated
Study start2002-08 (month precision)
Primary completion2003-05actual (month precision)
Study completion2003-05actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Subjects with type 2 diabetes
•Treated with diet and exercise alone or with metformin for at least 3 months prior to screening
•BMI 27-45 kg/m^2
•HbA1c between 7.0 % and 8.0 %

Exclusion criteria

•Treated with other oral anti-diabetic agents other than metformin within 3 months of screening
•Patients previously treated with AC2993
•Patients presently treated with insulin

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28

Time frame:Baseline (Day 1) to Day 28

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c from Baseline to Day 14

Time frame:Baseline, Day 14

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in fasting plasma glucose from Baseline to Day 14 and to Day 28

Time frame:Baseline, Day 14, Day28

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in serum fructosamine from Baseline (Day 1) to Day 14 and to Day 28

Time frame:Baseline, Day 14, Day 28

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.